GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stem Cells Spin SA (WAR:SCS) » Definitions » EV-to-EBITDA

Stem Cells Spin (WAR:SCS) EV-to-EBITDA : 21.75 (As of Jun. 03, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Stem Cells Spin EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stem Cells Spin's enterprise value is zł19.42 Mil. Stem Cells Spin's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was zł0.89 Mil. Therefore, Stem Cells Spin's EV-to-EBITDA for today is 21.75.

The historical rank and industry rank for Stem Cells Spin's EV-to-EBITDA or its related term are showing as below:

WAR:SCS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -501.71   Med: 23.24   Max: 366.99
Current: 21.75

During the past 13 years, the highest EV-to-EBITDA of Stem Cells Spin was 366.99. The lowest was -501.71. And the median was 23.24.

WAR:SCS's EV-to-EBITDA is ranked worse than
71.24% of 452 companies
in the Biotechnology industry
Industry Median: 9.47 vs WAR:SCS: 21.75

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Stem Cells Spin's stock price is zł0.47. Stem Cells Spin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was zł-0.005. Therefore, Stem Cells Spin's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Stem Cells Spin EV-to-EBITDA Historical Data

The historical data trend for Stem Cells Spin's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stem Cells Spin EV-to-EBITDA Chart

Stem Cells Spin Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.49 62.61 38.47 12.08 15.08

Stem Cells Spin Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.63 15.01 17.47 15.08 21.75

Competitive Comparison of Stem Cells Spin's EV-to-EBITDA

For the Biotechnology subindustry, Stem Cells Spin's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stem Cells Spin's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stem Cells Spin's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stem Cells Spin's EV-to-EBITDA falls into.



Stem Cells Spin EV-to-EBITDA Calculation

Stem Cells Spin's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=19.420/0.893
=21.75

Stem Cells Spin's current Enterprise Value is zł19.42 Mil.
Stem Cells Spin's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stem Cells Spin  (WAR:SCS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Stem Cells Spin's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.47/-0.005
=At Loss

Stem Cells Spin's share price for today is zł0.47.
Stem Cells Spin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.005.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Stem Cells Spin EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stem Cells Spin's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Stem Cells Spin (WAR:SCS) Business Description

Traded in Other Exchanges
N/A
Address
Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.